Connect with us

Business

Apple News accused of left-leaning bias in new study of 620 stories

Published

on

Apple News accused of left-leaning bias in new study of 620 stories

Apple’s popular news app has been aggressively promoting articles from left-leaning news outlets – even as it has all but shut down posts from more conservative publications, according to an explosive study.

The Media Research Center, a conservative watchdog group focused on tracking media bias, analyzed a total of 620 stories that were featured by Apple News in high-traffic morning time slots between Jan. 1 and 31. The Apple News feed is a mixture of stories curated by a team of in-house editors and some by algorithm.

Advertisement

Of the 620 stories, a whopping 440 came from outlets that are rated as left-leaning, while the remaining 180 were published by centrist outlets. Meanwhile, outlets which are considered right-leaning – including The Post – were shut out entirely.

In January, Apple News featured a total of 72 articles by The Washington Post, 54 articles by The Associated Press, 50 by NBC News, 34 by The Guardian and 25 by NPR, according to MRC’s data. It published 54 Wall Street Journal articles. The numbers for The Post and Fox News were zero and zero, respectively.

GOOGLE, APPLE URGED BY HOUSE COMMITTEE TO PULL APPS TRACKING ICE AGENTS

People seen near Apple Store in Berlin

The Media Research Center found a whopping 440 out of 620 Apple News stories studied came from left-leaning outlets. (Sean Gallup/Getty Images / Getty Images)

MRC’s researchers relied on media bias ratings compiled by AllSides, a nonpartisan organization that uses a multi-partisan panel of experts – with two members from the left, two from the center and two from the right – that are trained to spot media bias.

Advertisement

It also conducts blind surveys of ordinary Americans, then averages both sets of results to come up with a rating.

AllSides’s experts did not participate in the MRC study or have any advance knowledge about its findings. Nevertheless, Julie Mastrine, who serves as director of AllSides’ media bias rating system, said she was “not surprised at all” by the results.

“The bottom line is that Americans that are relying on these Big Tech companies to provide them with news are not getting a balanced view and they’re not getting the full scope of perspectives available,” Mastrine said in an interview.

VARNEY: BIASED MEDIA NEEDS A COMPLETE CULTURE CHANGE

Advertisement

In a statement provided after this story was published, an Apple spokesperson said the News app “provides access to news spanning a wide range of topics from more than 3,000 publications including the Wall Street Journal, Fox News, Bloomberg, USA Today, Washington Examiner, New York Post, CBS News, local outlets, and more.”

“Apple News users can tailor the app to their interests by choosing to follow or block specific publications or topics,” the spokesperson added.

As of Monday, Apple News had gone 96 consecutive days without showcasing a story from a conservative publication in its top stories.

The president stands outdoors addressing journalists gathered with cameras and microphones.

MRC alleged that Apple News “broadly focused on President Donald Trump’s foreign policy and immigration policy in negative ways” during the analysis period. (Al Drago/Getty Images)

MRC, which began publishing data on news aggregators in November, said Apple News last published an article by a right-leaning source on Nov. 5, when it ran a story by British outlet The Telegraph about the civil war in the Sudan.

Advertisement

MRC noted that the Apple News feed “broadly focused on President Donald Trump’s foreign policy and immigration policy in negative ways” during that time period, including selecting “provocative headlines that raised doubts about Trump’s actions” as it related to immigration and foreign policy.

“Almost half of voting-age Americans own an Apple iPhone,” MRC’s Dan Schneider told The Post. “Of course, all its phones come pre-installed with Apple News. Swipe right and you’re inundated with Apple’s cherry-picked news stories. Most people don’t even know they are being fed a steady stream of leftist narratives.”

In 2023, AllSides conducted its own study of bias at the 10 most popular news aggregations services. Apple News was given a “lean left” rating, with only Yahoo News and Bing News deemed to be more skewed toward liberal views when curating stories.

“Right-leaning media is really underrepresented,” Mastrine said.

Advertisement

APPLE STRIKES MAJOR DEAL WITH GOOGLE TO POWER SIRI WITH GEMINI AI

From Jan. 1 to 12, MRC tracked the top 20 stories from AllSides-rated news outlets that appeared on Apple News at approximately 10 a.m. ET. From Jan. 12 to 31, MRC did the same, but checked the Apple News app at 8:30 a.m. ET.

Schneider said MRC “experimented with different times” to see if it altered the results, but aimed to review Apple News in the morning for consistency.

The 620 articles included in MRC’s breakdown for January includes 30 stories by The Athletic, the sports site owned by the New York Times. The Times itself stopped participating with Apple News in 2020. The number also includes 27 pieces of original Apple content, most of which were links to its “Apple News Today” daily podcast.

Advertisement

“It is a subliminal form of propaganda, paid for with corporate dollars but without campaign finance disclosures,” Schneider added. “It could be illegal.”

social media apps

MRC’s Dan Schneider told the New York Post that Apple News’ behavior “is a subliminal form of propaganda.” (iStock)

The allegations are a potential headache for Apple and its CEO Tim Cook, who has cozied up to President Trump since he re-entered office last year. Key Trump-appointed federal regulators are actively looking to crack down on media bias in Big Tech and beyond.

In February 2024, FTC Chairman Andrew Ferguson launched an inquiry into tech censorship and said his agency wanted to “better understand how these firms may have violated the law by silencing and intimidating Americans for speaking their minds.”

The FTC also cleared a major merger between ad giants Omnicom and Interpublic on the condition that they refrain from anything resembling politically-motivated ad boycotts in the future.

Advertisement

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Elsewhere, FCC Commissioner Brendan Carr, a fierce Trump ally, infamously blasted Jimmy Kimmel last September over inflammatory comments he made about the killing of conservative influencer Charlie Kirk.

This week, Carr’s FCC opened a probe into ABC’s “The View” and whether it has broken rules requiring equal time for interviews with political candidates.

Advertisement
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Hershey introduces Dot’s original snack mix

Published

on

Hershey introduces Dot’s original snack mix

Features a blend of Dot’s Original snack pieces.

Continue Reading

Business

Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Medtronic plc (MDT) Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDT

Company Participants

Thierry Pieton – Executive VP & CFO

Conference Call Participants

Advertisement

Michael Kratky – Leerink Partners LLC, Research Division

Presentation

Michael Kratky
Leerink Partners LLC, Research Division

Advertisement

All right. I think we can kick things off. But thank you all for joining. My name is Mike Kratky. I’m our Senior MedTech Analyst at Leerink and thrilled to be joined today by Medtronic’s CFO, Thierry Pieton. So thanks so much for joining.

Thierry Pieton
Executive VP & CFO

Yes. Thanks for having me.

Advertisement

Question-and-Answer Session

Michael Kratky
Leerink Partners LLC, Research Division

Advertisement

You just passed the 1-year mark at Medtronic. We’d love to maybe kick it off by hearing from your perspective, how the business has evolved over the last year. And as you look out over the next 12 months, what gets you most excited?

Thierry Pieton
Executive VP & CFO

Yes. Look, first of all, it’s been an interesting 12 months. I mean we’ve had a lot of things going on between sort of accelerating some of the new product launches and some of the portfolio actions that we’ve taken that I’m sure we’ll talk about, the IPO of MiniMed and we’re going back on offense in M&A, and we’ve done a couple of things in the last 3 or 4 months. So it’s been pretty busy. Look, I think the business has growing confidence.

Advertisement

I think a lot of the work that has been done for several years in the past few years to build the portfolio and to reinforce some of the operating mechanisms in the team and to work on R&D on some of the innovations that we’re launching now, it’s starting to pay off. And I think there’s a lot of excitement

Advertisement
Continue Reading

Business

More support as heating oil costs 'double'

Published

on

More support as heating oil costs 'double'

Rural farmers and homeowners are struggling to afford heating oil as prices rise.

Continue Reading

Business

Outlook For Global Economy As Middle East Conflict Creates A Critical 'Chokepoint'

Published

on

Outlook For Global Economy As Middle East Conflict Creates A Critical 'Chokepoint'

Outlook For Global Economy As Middle East Conflict Creates A Critical 'Chokepoint'

Continue Reading

Business

Paro expands South Asian-inspired portfolio

Published

on

Paro expands South Asian-inspired portfolio

Company adds lentil crisps to expand its lentil-focused product line. 

Continue Reading

Business

Apura Ingredients, New Tree Fruit Co. form partnership

Published

on

Apura Ingredients, New Tree Fruit Co. form partnership

Partnership integrating NewTree’s “de-sugared” fruit technology into Apura’s portfolio. 

Continue Reading

Business

Rambus SVP, general counsel Shinn sells $404k in stock

Published

on


Rambus SVP, general counsel Shinn sells $404k in stock

Continue Reading

Business

Geox FY2025 presentation: net loss halved despite 8% sales decline

Published

on

Geox FY2025 presentation: net loss halved despite 8% sales decline


Geox FY2025 presentation: net loss halved despite 8% sales decline

Continue Reading

Business

Total Energy Services Inc. (TOT:CA) Q4 2025 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Conference Call Participants

Josef Schachter – Schachter Energy Research Services Inc.
Tim Monachello – ATB Cormark Capital Markets Inc., Research Division

Presentation

Advertisement

Operator

Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome you to the Total Energy Services Fourth Quarter and Full Year 2025 Results Conference Call. [Operator Instructions] Thank you.

I would now like to turn the conference over to Mr. Daniel Halyk, President and Chief Executive Officer. Please go ahead.

Advertisement

Daniel Halyk
President, CEO & Director

Thank you, Krista. Good morning, and welcome to Total Energy Services Fourth Quarter 2025 Conference Call. Present with me is Yuliya Gorbach, Total’s VP, Finance and CFO. We will review with you Total’s financial and operating highlights for the 3 months ended December 31, 2025, and then provide an outlook for our business and open up the phone lines for questions. Yuliya, please go ahead.

Yulia Gorbach
VP of Finance & CFO

Advertisement

Thank you, Dan. During the course of this conference call, information may be provided containing forward-looking information concerning Total’s projected operating results, anticipated capital expenditure trends and projected activity in the oil and gas field industry. Actual events or results may differ materially from those reflected in Total’s forward-looking statements due to a number of risks, uncertainties and other factors affecting Total’s businesses and the oil and gas service industry in general. These risks, uncertainties and other factors are described under the heading Risk Factors and elsewhere in Total’s most recently filed annual information form and other documents filed with Canadian provincial securities authorities that are available

Advertisement
Continue Reading

Business

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (XERS) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT

Company Participants

John Shannon – CEO & Director
Steven Pieper – Chief Financial Officer

Conference Call Participants

Advertisement

Jenna Davidner – Barclays Bank PLC, Research Division

Presentation

Jenna Davidner
Barclays Bank PLC, Research Division

Advertisement

All right. I think we’re all set.

Good morning. It’s still morning. Good morning, and welcome to the Barclays Miami Healthcare Conference. My name is Jenna Davidner. I’m one of the analysts here on the Specialty Pharmaceuticals team. And on stage with me, I have Xeris Biopharma. And from the company, we have the CEO, John Shannon. And on the end, we have Steve Pieper, the CFO.

Thank you, guys, for joining, and welcome to the conference.

Advertisement

John Shannon
CEO & Director

Thanks for having us.

Advertisement

Question-and-Answer Session

Jenna Davidner
Barclays Bank PLC, Research Division

So maybe just to level set the conversation, John, can you just give investors that are less familiar a brief overview of the company and your current product portfolio?

Advertisement

John Shannon
CEO & Director

Yes. I’ll just go really high level because I know we’re going to dig into some of this. So Xeris is a — it’s a fast-growing commercial biopharma company. We have 3 commercial products on the market, Gvoke for hypoglycemia. It’s a rescue pen for hypoglycemia, basically an EpiPen for diabetics.

Keveyis. Keveyis is for primary periodic paralysis, which is an ultra-rare hereditary genetic disorder. We can talk a little bit about that asset in a little bit. And then Recorlev. Recorlev is for hypercortisolemia and Cushing’s syndrome, which is our big grower in the business.

On top of that, we have XP-8121, which is our next potential blockbuster, and that’s a once-weekly subcu levothyroxine for hypothyroidism. And that’s Phase III ready. We’re going to get that

Advertisement
Continue Reading

Trending

Copyright © 2025